Mercy Health is committed to fighting cancer in all its forms, and part of that fight is investing in medical research and clinical trials to find new ways to battle the disease.
Oncology Clinical Trials
Paducah, KY
A Phase 3 Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Previously Treated Mantle Cell Lymphoma
Patients must have histologically confirmed mantle cell lymphoma and previously treated with at least one line of therapy. They will be randomized to either receive LOXO-305 200mg daily by mouth versus Investigator Choice of oral BTK Inhibitor of Ibrutinib, acalabrutinib or zanubrutinib. Study treatment will be given continuously until progressive disease, unacceptable toxicity, withdrawal of consent, death or initiation of a new anticancer treatment. Adult patient can receive any previously number of prior lines of therapy but must not have been treated with a BTK inhibitor, approved or investigational.
18 years of age and older
Study Number: NCT04662255
Please call 270-538-5632 to learn more.
A Phase 3 Study Comparing LOXO-305 to Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab
Patient must have confirmed diagnosis of CLL/SLL. Patient will be randomized to receive either oral LOXO 305 200mg daily or Investigator's Choice of either Idelalisib(oral) plus Rituximab(IV) or Bendamustine/Rituximab(both IV). Treatment will continue until progression, unacceptable toxicity, or other reason for treatment discontinuation. Patients need to be previously treated with a covalent BTK inhibitor, investigational or approved, and either alone or in combination with other agents. Patients may have received an unlimited number of lines of prior therapy.
18 years of age and older
Study Number: NCT04666038
Please call 270-538-5632 to learn more.
A Phase 3, Open-Label, Randomized Study to Compare The Efficacy and Safety of Luspatercept(ACE-536) Versus Epoetin Alfa For The Treatment of Anemia Due To IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes(MDS) in ESA Naive Subjects Who Require Red Blood Cell Transfusions
Patient must have a documented diagnosis of MDS of very low, low or intermediate risk disease. They must be erythropoiesis stimulating agent (ESA) naïve subjects who require red blood cell (RBC) transfusions (ie, 2 to 6 packed red blood cell (pRBC) units in the 8 weeks before randomization). A bone marrow aspiration and biopsy will be performed at screening to confirm diagnosis. They will be randomized to receive either Luspatercept SQ every 3 weeks versus Epoetin Ala SQ weekly. Patient will receive treatment through a minimum of 24 weeks when a MDS Disease Assessment Visit will be scheduled to include a repeat bone marrow aspiration and biopsy to check disease status unless they experience unacceptable toxicities, withdraws consent or meets any other treatment discontinuation criteria.
18 years of age and older
Study Number: NCT03682536
Please call 270-538-5632 to learn more.
A Phase 3 Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab with or without Lenvatinib in Participants with Metastatic NonSquamous Non-Small Cell Lung Cancer
Patient must have histologically or cytologically confirmed diagnosis of Stage IV non-squamous Non-Small Cell Lung Cancer who have not received systemic anticancer therapy for their metastatic disease and are at least 18 years of age may be enrolled in this study. The investigator will select a platinum(carboplatin or cisplatin) doublet chemotherapy regimen prior to randomization. All participants will also receive pembrolizumab 200 mg IV every 3 weeks for up to a total of 35 cycles and lenvatinib/matching placebo until reaching a discontinuation criterion. Treatment with pembrolizumab and chemotherapy in this study is open-label. The participant can continue on the study until they have any progression of disease or recurrence of any malignancy, or any occurrence of another malignancy that requires active treatment, unacceptable toxicity or Investigator’s decision to discontinue treatment.
18 years of age and older
Study Number: NCT03829319
Please call 270-538-5632 to learn more.
